J.P. Morgan 2024: Illumina, 10x, Danaher, AI; Liberate Bio

Episode 4 (January 12, 2024): Takeaways from the J.P. Morgan Health Care conference: Illumina, Danaher, 10x, Empress Therapeutics; an interview with Liberate Bio’s Shawn Davis and Walter Strapps.

Listed below are references to relevant GEN stories discussed in this episode of Touching Base:

JPM: Illumina’s new CEO spells out 2024 priorities, presents preliminary Q4 2023 results
By Alex Philippidis, GEN, January 10, 2024.

JPM: Prime Medicine eyes 2024 IND for first prime editing therapy
By Alex Philippidis, GEN, January 9, 2024

JPM 2024: Veracyte’s C2i genomics acquisition adds AI readouts to liquid biopsy testing
By Jonathan D. Grinstein, GEN, January 8, 2024

JPM: More M&A “firepower” in store for 2024, EY predicts
By Alex Philippidis, GEN, January 8, 2024


To access all episodes of Touching Base click here.